MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced upcoming presentations of data on the Company’s proprietary programs at the 57th American Society of Hematology (ASH) Annual Meeting, being held December 5-8, 2015 in Orlando, Florida. Presentations will feature pre-clinical and clinical data for MorphoSys’s proprietary programs MOR208 and MOR202.
“We believe the promising new pre-clinical and clinical data being presented for our proprietary portfolio will further demonstrate the potential of MOR208 and MOR202 as important treatment options for patients with B-cell malignancies and multiple myeloma, respectively,” commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. “We intend to start additional clinical trials of MOR208 in combination regimens to assess the potential benefit of such regimens for patients with CLL and DLBCL.”
Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma The poster presentation will include updated clinical results from the MOR208 monotherapy trial in adult patients with relapsed/refractory NHL.
Abstract #1528
Poster session 624: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models
Date: Saturday, December 5, 2015, 5:30pm - 7:30pm EST (11:30pm CET, 10:30pm GMT)
A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)
The poster presentation will include first safety and efficacy results from the ongoing trial of MOR208 in combination with lenalidomide.
Abstract #2953
Poster session 642: CLL: Therapy, excluding Transplantation
Date: Sunday, December 6, 2015, 6:00pm - 8:00pm EST (0:00 am CET (Dec. 7), 11:00pm GMT)
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma The poster presentation will include updated safety and efficacy results from the ongoing MOR202 dose-escalation study in multiple myeloma patients. Data will be presented from the highest dose cohort of MOR202 as monotherapy, as well as from the first two cohorts of patients receiving MOR202 in combination with lenalidomide and pomalidomide.
Abstract #3035
Session Name: 653. Myeloma: Therapy, excluding Transplantation
Date: Sunday, December 6, 2015, 6:00pm - 8:00pm EST (0:00 am CET (Dec. 7), 11:00pm GMT)
MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds
Abstract #3015
Poster session 652: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
Date: Sunday, December 6, 2015, 6:00pm - 8:00pm EST (0:00 am CET (Dec. 7), 11:00pm GMT)
Lenalidomide enhances MOR202 dependent macrophage-mediated effector functions via the vitamin D pathway
Abstract #2203
Poster session 201: Granulocytes, Monocytes and Macrophages
Date: Sunday, December 6, 2015, 6:00pm - 8:00pm EST (0:00 am CET (Dec. 7), 11:00pm GMT)
Additional information can be found at www.hematology.org, including the abstracts.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties, Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
Help employers find you! Check out all the jobs and post your resume.
